CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immunicon Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immunicon Corp.
Suite 100, 3401 Masons Mill Road
Phone: (215) 830-0777p:215 830-0777 HUNTINGDON VALLEY, PA  19006  United States Fax: (215) 830-0751f:215 830-0751

This company is no longer actively traded on any major stock exchange.

Business Summary
Immunicon Corporation has developed and commercialized its own cell- and molecular-based human diagnostic and life science research products, and provided certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. In August 2008, Immunicon and its wholly owned subsidiaries completed the sale of substantially all of their assets to Veridex, LLC.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200812/31/2007YesYesYes--

Industries
SIC Code Description
3826 Laboratory analytical instruments

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board J. WilliamFreytag 6/18/2007 1/1/1998
President, Chief Executive Officer, Director Byron D.Hewett 57 1/1/2006 10/12/2004
Senior Vice President, R&D and Chief Scientific Officer Leon W.Terstappen 57 1/1/1999 1/1/1999
5 additional Officers and Directors records available in full report.

Business Names
Business Name
IMMC Holdings, Inc.
Immunicon Europe, Inc.
Immunivest Corporation

General Information
Stock Exchange: OTC
Federal Tax Id: 232269490
Fax Number: (215) 830-0751


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 5, 2021